Taking on Metabolic & Neurodegenerative Disorders
Deep Genomics to identify oligonucleotide candidates for treating genetically defined metabolic and neurodegenerative disorders
For the first time, machine learning will be used at every step of drug discovery to identify candidates for treating genetically defined metabolic and neurodegenerative disorders.
TORONTO, Ontario, Canada, March 26, 2018 - Deep Genomics, the leading AI therapeutics company that has built a platform using ...